Four in 10 prescription claims for the 26 new medicines reviewed by ICER between 2022 and 2025 were rejected by health insurers.
Agree
Disagree
Overview
Debates
Related claims
Topics
Sources
From the article
Most new drugs are still too costly at launch, ICER says
5
52c7ae14
Article
Most new drugs are still too costly at launch, ICER says
0